Flagship Pioneering-founded Alltrna is developing tRNA therapies to address genetic diseases driven by truncated versions of proteins. By addressing an aberrant genetic instruction underpinning many diseases, the startup is developing what it describes as a potential “universal solution.”
Researchers at the Forsyth Institute have discovered an important mechanism that may have profound implications for how we prevent colorectal cancer. Oddly enough, their discovery began in the mouth.
Nascent polypeptide chains or polypeptidyl-tRNAs (pep-tRNAs) occur transiently during protein synthesis. The potential to study these intermediates and better understand their role in processes like gene regulation has been greatly enhanced by the development of a process termed PETEOS short for peptidyl-tRNA enrichment using organic extraction and silica adsorption.